等待开盘 05-20 09:30:00 美东时间
+3.500
+1.82%
Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, today announced that the U.S. Food and Drug Administration (FDA) has approved Signatera CDx as a companion diagnostic (CDx) for use
05-16 00:47
今日重点评级关注:HC Wainwright & Co.:维持Caribou Biosciences"买入"评级,目标价从9美元升至11美元;康托·菲茨杰拉德:维持Artiva Biotherapeutics"超配"评级,目标价从10美元升至40美元
05-12 12:36
今日重点评级关注:HC Wainwright & Co.:维持Artiva Biotherapeutics"买入"评级,目标价从15美元升至35美元;韦德布什:维持Cullinan Therapeutics"跑赢大市"评级,目标价从36美元升至37美元
05-11 15:43
Evercore ISI Group analyst Daniel Markowitz maintains Natera (NASDAQ:NTRA) with a Outperform and raises the price target from $250 to $270.
05-08 22:00
华盛资讯5月8日讯,Natera, Inc.公布2026财年Q1业绩,公司Q1营收6.97亿美元,同比增长38.8%,归母净利润亏损0.85亿美元,同比亏损扩大27.1%。
05-08 05:48
Natera (NASDAQ:NTRA) raises FY2026 sales outlook from $2.620 billion-$2.700 billion to $2.740 billion-$2.820 billion vs $2.668 billion estimate.
05-08 04:14
Natera (NASDAQ:NTRA) reported quarterly losses of $(0.60) per share which missed the analyst consensus estimate of $(0.57) by 5.26 percent. This is a 20 percent decrease over losses of $(0.50) per share from the same
05-08 04:13
https://www.wsj.com/tech/ai/ai-investor-coatue-joins-data-center-frenzy-with-new-venture-to-buy-land-9f4c374f?reflink=desktopwebshare_permalink
05-01 21:51
William Blair starts Natera coverage, citing MRD growth potential, strong moat, and diversified pipeline supporting long-term outlook.
04-15 02:30